More stories
Auto Physical Damage
News Release
Battery Electric Vehicle Collision Claims Continue to Rise Despite Sales Slowdown
Mitchell today published its Q2 2024 Plugged-In: EV Collision Insights report. This edition features the latest U.S. and Canadian claims data on battery electric vehicles (BEVs), mild hybrid electric vehicles (MHEVs) and plug-in hybrid electric vehicles (PHEVs)—highlighting how differences in their complexity and construction are affecting claim costs and repair operations.
Auto Physical Damage
Article
Plugged-In: EV Collision Insights Q2 2024
Claims frequency for repairable, collision-damaged battery electric vehicles (BEVs) rose to 2.5% in the U.S. and 3.94% in Canada in Q2 2024—a year-over-year increase of 45% and 39% respectively. According to the Alliance for Automotive Innovation, EVs represented 9.3% of new U.S. light-duty vehicle sales in Q1 2024, down from 10.2% in Q4 2023. Similarly, in Canada BEV sales fell to 9.2% last quarter, down from 10% in Q4 2023.
WorkCompWire
Article
An Overlooked Essential: Hospital Discharge Planning in Workers’ Compensation
In a recent article, Jim Begg, Vice President of National Accounts for Apricus, highlights the critical role of effective discharge planning in helping patients recover swiftly and safely.
Enlyte
Article
Bridging the Gap for New Adjusters with Innovative Tools
Streamline your claims process and support your team with our cutting-edge solutions.
Auto Physical Damage
Conference
SEMA 2024
The SEMA Show is the premier destination for manufacturers and buyers looking to discover thousands of the latest innovations in the automotive aft
Enlyte
Podcast
New Trends in Opioids and Pain Management
Despite decreases in utilization and cost per claim, opioids remain the No. 1 drug class in Enlyte’s 2024 Drug Trends Report. However, due to concerns with safety and overutilization, increased focus on usage guidelines as well as alternatives to pain management are gaining momentum — including those whose active ingredients drive from things you might not imagine, like pufferfish, cacti and chili peppers. Enlyte’s Nikki Wilson explores this and more in our Part 3 drug trends analysis.